Skip to main content
Equibles
GANX logo

GANX · Gain Therapeutics, Inc. · Investor Relations

Track GANX — free

Use GANX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GANX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.26 -0.03 (-2.33%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the second quarter of 2027.”
View the 10-Q filed Aug 11, 2026
Market Cap
$54.99M
Shares
43.64M
Volume · Oct 23 645.03K Avg daily vol (3M) 503.57K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Key facts CIK 1819411 CUSIP 36269B105 13F (30d) 5 filings 5 filers Visit website Investor relations